Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY24 results · Oct–Dec 2023
Torrent Pharmaceuticals reported revenue from operations of ₹2,732.00 crore (up 9.7% from Q3 FY23) and net profit of ₹443.00 crore (up 56.5% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,732.00 | 2,491.00 | +9.7% | 2,660.00 | +2.7% |
| Other income | (33.00) | (10.00) | Loss widened | 26.00 | Turned loss |
| Total income | 2,699.00 | 2,481.00 | +8.8% | 2,686.00 | +0.5% |
| Profit before tax | 631.00 | 419.00 | +50.6% | 559.00 | +12.9% |
| Net profit for the period | 443.00 | 283.00 | +56.5% | 386.00 | +14.8% |
| Attributable to shareholders of the company | 442.00 | 283.00 | +56.2% | 363.00 | +21.8% |
| EPS, basic (₹) | 13.10 | 8.36 | +56.7% | 11.39 | +15.0% |
| Net margin (%) | 16.2 | 11.4 | 14.5 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,123.00 | 1,857.00 | +14.3% | 2,146.00 | −1.1% |
| Other income | (11.00) | 15.00 | Turned loss | 15.00 | Turned loss |
| Total income | 2,112.00 | 1,872.00 | +12.8% | 2,161.00 | −2.3% |
| Profit before tax | 430.00 | 353.00 | +21.8% | 482.00 | −10.8% |
| Net profit for the period | 297.00 | 229.00 | +29.7% | 327.00 | −9.2% |
| EPS, basic (₹) | 8.78 | 6.78 | +29.5% | 9.65 | −9.0% |
| Net margin (%) | 14.0 | 12.3 | 15.2 |
Consolidated
- Filed with BSE
- 02 Feb 2024, 18:08 IST
- Board meeting
- 02 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Feb 2024, 18:08 IST
- Board meeting
- 02 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Audited
- Source
- XBRL filing on BSE